Home Biosimilar Antibodies Others Others Atibuclimab (Anti-CD14)
For research use only. Not for use in humans.

Atibuclimab (Anti-CD14)

Synonyms: LPS receptor， Monocyte differentiation antigen CD14

Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD.

Atibuclimab (Anti-CD14)

Quality Control

Batch: A256601 Purity: 99% Protein concentration: 8.23mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD.

Product Details

CAS No. 2417175-94-9
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06513949 RECRUITING Acute Respiratory Distress Syndrome; Adult Respiratory Distress Syndrome; Acute Lung Injury; Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Implicit Bioscience 2026-06-17 PHASE2
NCT07481474 NOT_YET_RECRUITING Knee Osteoarthritis (Knee OA) VA Office of Research and Development 2027-01-01 PHASE1
NCT06678074 ACTIVE_NOT_RECRUITING Drug: Atibuclimab (IC14), 20 mg/kg intravenously, once STEMI; STEMI (ST Elevation MI); STEMI - ST Elevation Myocardial Infarction (MI); Stent Implantation Implicit Bioscience 2025-02-06 PHASE1; PHASE2
NCT06556810 ACTIVE_NOT_RECRUITING Drug: Atibuclimab (IC14) Acute Decompensated Heart Failure Implicit Bioscience 2024-10-17 PHASE1; PHASE2
NCT04391309 TERMINATED Drug: remdesivir Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) National Institute of Allergy and Infectious Diseases (NIAID) 2021-04-12 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.